Triple negative breast cancer is an especially appealing malignancy for treatment with Chk1 inhibitors, since these cancers have faulty replication fork repair, either from inherited or acquired BRCA1/2 deficiencies. The gene discussed is BRCA1; the disease is triple-negative breast carcinoma.